SpringWorks rises after report Germany's Merck has made nearly $3.5 billion deal
** Shares of drugmaker SpringWorks Therapeutics SWTX.O rise 8.2% to $44.59 ** Germany's Merck KGaA MRCG.DE is nearing a roughly $3.5 billion deal for SWTX, the Wall Street Journal reports ** Both companies have agreed on a price close to $47 per share, report says ** Up to last close, SWTX up 14% YTD (Reporting by Juby Babu in Mexico City) ((Juby.Babu@thomsonreuters.com;))
Recent news on SpringWorks Therapeutics
See all newsBrief: Merck KGaA Completes Acquisition Of Springworks Therapeutics
Brief: Springworks Therapeutics Expects Nirogacestat Decision From European Commission In Q3
Brief: EMA's CHMP Re-Examines Rejection Of Kisunla For Early Alzheimer’S Treatment
Brief: SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
Brief: SpringWorks Therapeutics Receives Positive CHMP Opinion For Mirdametinib For The Treatment Of Adult And Pediatric Patients With NF1-PN